Potent cholesteryl ester transfer protein inhibitors of reduced lipophilicity: 1,1′-spiro-substituted hexahydrofuroquinoline derivatives

Journal of Medicinal Chemistry

Volumn 57, Issue 21, 2014, Pages 8766-8776

  Trieselmann, Thomas ^a   Wagner, Holger ^a   Fuchs, Klaus ^a   Hamprecht, Dieter ^b   Berta, Daniela ^b   Cremonesi, Paolo ^b   Streicher, Rüdiger ^a   Luippold, Gerd ^a   Volz, Astrid ^a   Markert, Michael ^a   Nar, Herbert ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b BI Research Italia Sas of BI IT Srl   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 [9' HYDROXY 4' ISOPROPYL 7',7' DIMETHYL 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLINE) 3' YL]PHENYL] 2 METHYLPROMANENITRILE; 3' (4 FLUOROPHENYL) 4' ISOPROPYL 7',7' DIMETHYL 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; 3' (4 TERT BUTYLPHENYL) 4' ISOPROPYL 7',7' DIMETHYL 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLINE) 9' OL; 4 (9' HYDROXY 4' ISOPROPYL 7',7' DIMETHYL 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLINE) 3' YL]BENONITRILE; 4 ISOPROPYL 7,7 DIMETHYL 3 [4 (TRIFLUOROMETHYL)PHENYL] 2',3',5',6,6',7,8,9 OCATHYDRO 3H SPIRO(FURO[3,4 C]QUINOLINE 1,4' PYRAN) 9 OL; 4' CYCLOPENTYL 7',7' DIMETHYL 3' [4 (TRIFLUOROMETHYL)PHENYL] 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; 4' ETHYL 7',7' DIMETHYL 3' [4 (TRIFLUOROMETHYL)PHENYL] 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; 4' ISOPROPYL 1,1,7,7 TERTAMETHYL 3 [4 (TRIFLUOROMETHYL)PHENYL] 1,3,6,7,8,9 HEXAHYHYDRO[3,4 C]QUINOLIN 9' OL; 4' ISOPROPYL 7',7' DIMETHYL 3' [3 (TRIFLUOROMETHYL)PHENYL] 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; 4' ISOPROPYL 7',7' DIMETHYL 3' [4 (TRIFLUOROMETHOXY)PHENYL] 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; 4' ISOPROPYL 7',7' DIMETHYL 3' [4 (TRIFLUOROMETHYL)PHENYL] 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; 4' ISOPROPYL 7',7' DIMETHYL 3' [5 (TRIFLUOROMETHYL)PYRIDIN 2 YL] 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; 4' ISOPROPYL 7',7' DIMETHYL 3' [6 (TRIFLUOROMETHYL)PYRIDIN 3 YL] 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; 4' ISOPROPYL 7',7' DIMETHYL 4' 3' [4 (TRIFLUOROMETHYL)PHENYL] 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; 7',7' DIMETHYL 3' PHENYL 4' (PROPAN 2 YL) 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLINE) 9' OL; 7',7' DIMETHYL 4' (TETRAHYDRO 2H PYRAN 4 YL) 3' [4 (TRIFLUOROMETHYL)PHENYL] 6',7',8',9' TETRAHYDRO 3' H SPIRO(CYCLOPENTANE 1,1' FURO[3,4 C]QUINOLIN) 9' OL; ALDOSTERONE; ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; QUINOLINE DERIVATIVE; TORCETRAPIB; UNCLASSIFIED DRUG; 4-ISOPROPYL-7,7-DIMETHYL-3-(4-(TRIFLUOROMETHYL)PHENYL)-2′,3′,5′,6,6′,7,8,9-OCTAHYDRO-3H-SPIRO(FURO(3,4-C)QUINOLINE-1,4′-PYRAN)-9-OL; CETP PROTEIN, HUMAN; CHOLESTEROL ESTER TRANSFER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; QUINOLINOL DERIVATIVE; SPIRO COMPOUND;

ALDOSTERONE RELEASE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIASTEREOISOMER; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG POTENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HYDROGENATION; LIPOPHILICITY; MACACA FASCICULARIS; MALE; MOUSE; NONHUMAN; PR INTERVAL; QRS COMPLEX; QT INTERVAL; REDUCTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SUZUKI REACTION; TANDEM MASS SPECTROMETRY; TRANSGENIC MOUSE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; SYNTHESIS;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; HUMANS; HYDROXYQUINOLINES; MACACA FASCICULARIS; MICE, TRANSGENIC; QUINOLINES; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84923775095     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm500431d     Document Type: Article

References (35)

1. OKeefe, J. H.; Cordain, L.; Harris, W. H.; Moe, R. M.; Vogel, R. Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal J. Am. Coll. Cardiol. 2004, 43, 2142-2146
2. Kearney, P. M.; Blackwell, L.; Collins, R.; Keech, A.; Simes, J.; Peto, R.; Armitage, J.; Baigent, C. Efficacy of cholesterol-lowering therapy in 18686 people with diabetes in 14 randomised trials of statins: A meta-analysis Lancet 2008, 371, 117-125
3. Baigent, C.; Keech, A.; Kearney, P. M.; Blackwell, L.; Buck, G.; Pollicino, C.; Kirby, A.; Sourjina, T.; Peto, R.; Collins, R.; Simes, J. Efficacy and safety of cholesterol-lowering treatment: Prospective metaanalysis of data from 90056 participants in 14 randomised trials of statins Lancet 2005, 366, 1267-1278
4. Brunzell, J. D.; Davidson, M.; Furberg, C. D.; Goldberg, R. B.; Howard, B. V.; Stein, J. H.; Witztum, J. L.; American Diabetes Association; American College of Cardiology Foundation Lipoprotein management in patients with cardiometabolic risk Diabetes Care 2008, 31, 811-822
5. Gordon, T.; Castelli, W. P.; Hjortland, M. C.; Kannel, W. B.; Dawber, T. R. High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study Am. J. Med. 1977, 62, 707-714
6. Drexel, H. Reducing risk by raising HDL-cholesterol: The evidence Eur. Heart J. Suppl. 2006, 8, F23-F29
7. Tall, A. R.; Yvan-Charvet, L.; Terasaka, N.; Pagler, T.; Wang, N. HDL, ABC transporters, and cholesterol efflux: Implications for the treatment of atherosclerosis Cell Metab. 2008, 7, 365-375
8. Barkowski, R. S.; Frishman, W. H. HDL metabolism and CETP inhibition Cardiol. Rev. 2008, 16, 154-162
9. Schwartz, G. G.; Olsson, A. G.; Abt, M.; Ballantyne, C. M.; Barter, P. J.; Brumm, J.; Chaitman, B. R.; Holme, I. M.; Kallend, D.; Leiter, L. A.; Leitersdorf, E.; McMurray, J. J. V.; Mundl, H.; Nicholls, S. J.; Shah, P. K.; Tardif, J.-C.; Wright, R. S.; for the dal-OUTCOMES Investigators Effects of dalcetrapib in patients with a recent acute coronary syndrome N. Engl. J. Med. 2012, 367, 2089-2099
10. Cannon, C. P.; Shah, S.; Dansky, H. M.; Davidson, M.; Brinton, E. A.; Gotto, A. M.; Stepanavage, M.; Liu, S. X.; Gibbons, P.; Ashraf, T. B.; Zafarino, J.; Mitchel, Y.; Barter, P. N. Safety of anacetrapib in patients with or at high risk for coronary heart disease N. Engl. J. Med. 2010, 363, 2406-2415
11. Nicholls, S. J.; Brewer, H. B.; Kastelein, J. J.; Krueger, K. A.; Wang, M. D.; Shao, M.; Hu, B.; McErlean, E.; Nissen, S. E. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial JAMA, J. Am. Med. Assoc. 2011, 306, 2099-2109
12. Qiu, X.; Mistry, A.; Ammirati, M. J.; Chrunyk, B. A.; Clark, R. W.; Cong, Y.; Culp, J. S.; Danley, D. E.; Freeman, T. B.; Geoghegan, K. F.; Griffor, M. C.; Hawrylik, S. J.; Hayward, C. M.; Hensley, P.; Hoth, L. R.; Karam, G. A.; Lira, M. E.; Lloyd, D. B.; McGrath, K. M.; Stutzman-Engwall, K. J.; Subashi, A. K.; Subashi, T. A.; Thompson, J. F.; Wang, I. K.; Zhao, H.; Seddon, A. P. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules Nat. Struct. Mol. Biol. 2007, 14, 106-113
13. Meanwell, N. A. Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety Chem. Res. Toxicol. 2011, 24, 1420-1456
14. Tarcsay, á.; Keseru, G. M. Contributions of Molecular Properties to Drug Promiscuity J. Med. Chem. 2013, 56, 1789-1795
15. Peters, J. U.; Schnider, P.; Mattei, P.; Kansy, M. Pharmacological promiscuity: Dependence on compound properties and target specificity in a set of recent Roche compounds Chem. Med. Chem. 2009, 4, 680-686
16. Perlman, M. E.; Murdande, S. B.; Gumkowski, M. J.; Shah, T. S.; Rodricks, C. M.; Thornton-Manning, J.; Freel, D.; Erhart, L. C. Development of a self-emulsifying formulation that reduces the food effect for torcetrapib Int. J. Pharm. 2007, 351, 15-22
17. Krishna, R.; Bergman, A. J.; Jin, B.; Fallon, M.; Cote, J.; Van Hoydonck, P.; Laethem, T.; Gendrano, I. N., III; Van Dyck, K.; Hilliard, D.; Laterza, O.; Snyder, K.; Chavez-Eng, C.; Lutz, R.; Chen, J.; Bloomfield, D. M.; De Smet, M.; Van Bortel, L. M.; Gutierrez, M.; Al-Huniti, N.; Dykstra, K.; Gottesdiener, K. M.; Wagner, J. A. Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Clin. Pharmacol. Ther. 2008, 84, 679-683
18. Dalvie, D.; Chen, W.; Zheng, C.; Vaz, A. D.; Smolarek, T. A.; Cox, L. M.; Lin, J.; Obach, R. S. Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans Drug Metab. Dispos. 2008, 36, 2185-2198
19. Krishna, R.; Garg, A.; Panebianco, D.; Cote, J.; Bergman, A. J.; Van Hoydonck, P.; Laethem, T.; Van Dyck, K.; Chen, J.; Chavez-Eng, C.; Archer, L.; Lutz, R.; Hilliard, D.; Snyder, K.; Jin, B.; Van Bortel, L.; Lasseter, K. C.; Al-Huniti, N.; Dykstra, K.; Gottesdiener, K.; Wagner, J. A. Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects Br. J. Clin. Pharmacol. 2009, 68, 535-545
20. Suico, J. G.; Wang, M. D.; Friedrich, S.; Cannady, E. A.; Konkoy, C. S.; Ruotolo, G.; Krueger, K. A. Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults J. Pharm. Pharmacol. 2014, 10.1111/jphp.12287
21. Forrest, M. J.; Bloomfield, D.; Briscoe, R. J.; Brown, P. N.; Cumiskey, A.-M.; Ehrhart, J.; Hershey, J. C.; Keller, W. J.; Ma, X.; McPherson, H. E.; Messina, E.; Peterson, L. B.; Sharif-Rodriguez, W.; Siegl, P. K. S.; Sinclair, P. J.; Sparrow, C. P.; Stevenson, A. S.; Sun, S.-Y.; Tsai, C.; Vargas, H.; Walker, M., III; West, S. H.; White, V.; Woltmann, R. F. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone Br. J. Pharmacol. 2008, 154, 1465-1473
22. Blasi, E.; Bamberger, M.; Knight, D.; Engwall, M.; Wolk, R.; Winter, S.; Betts, A.; John-Baptiste, A.; Keiser, J. Effects of CP-532,623 and Torcetrapib, Cholesteryl Ester Transfer Protein Inhibitors, on Arterial Blood Pressure J. Cardiovasc. Pharmacol. 2009, 53, 507-516
23. DePasquale, M.; Cadelina, G.; Knight, D.; Loging, W.; Winter, S.; Blasi, E.; Perry, D.; Keiser, J. Mechanistic studies of blood pressure in rats treated with a series of cholesteryl ester transfer protein inhibitors Drug Dev. Res. 2009, 70, 35-48
24. Hu, X.; Dietz, J. D.; Xia, C.; Knight, D. R.; Loging, W. T.; Smith, A. H.; Yuan, H.; Perry, D. A.; Keiser, J. Torcetrapib induces aldosterone and cortisol production by an intracellular calcium-mediated mechanism independently of cholesteryl ester transfer protein inhibition Endocrinology 2009, 150, 2211-2219
25. Bischoff, H.; Gielen-Haertwig, H.; Li, V.; Schmeck, C.; Thutewohl, M.; Vakolopoulos, A.; Weber, O.; Wuttke, M. Preparation of a quinolinol derivative useful for the treatment of cardiovascular diseases and as an inhibitor of cholesterol ester transfer protein. German Patent DE 102004061000, 2006.
26. Similar CETP-Inhibitors have been published in Schmeck, C.; Gielen-Haertwig, H.; Vakalopoulos, A.; Bischoff, H.; Li, V.; Wirtz, G.; Weber, O. Novel tetrahydrochinoline derived CETP inhibitors Bioorg. Med. Chem. Lett. 2010, 20, 1740-3
27. Mann, A. Conformational restriction and/or steric hindrance in medicinal chemistry. In The Practice of Medicinal Chemistry, 3 rd ed.; Wermuth, C. G., Ed.; Academic Press: Boston, MA, 2008; pp 363-379.
28. Eveland, S. S.; Milot, D. P.; Guo, Q.; Chen, Y.; Hyland, S. A.; Peterson, L. B.; Jezequel-Sur, S.; ODonnell, G. T.; Zuck, P. D.; Ferrer, M.; Strulovici, B.; Wagner, J. A.; Tanaka, W. K.; Hilliard, D. A.; Laterza, O.; Wright, S. D.; Sparrow, C. P.; Anderson, M. S. A high-precision fluorogenic cholesteryl ester transfer protein assay compatible with animal serum and 3456-well assay technology Anal. Biochem. 2007, 368, 239-249
29. Hett, R.; Senanayake, C. H.; Wald, A. S. Conformational toolbox of oxazaborolidine catalysts in the enantioselective reduction of α-bromo-ketone for the synthesis of (R,R,)-formoterol Tetrahedron Lett. 1998, 39, 1705-1708
30. Agellon, L. B.; Walsh, A.; Hayek, T.; Moulin, P.; Jiang, X.-C.; Shelanski, S. A.; Breslow, J. L.; Tall, A. R. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice J. Biol. Chem. 1991, 266, 10796-10801
31. Grass, D. S.; Saini, U.; Felkner, R. H.; Wallace, R. E.; Lago, W. J.; Young, S. G.; Swanson, M. E. Transgenic mice expressing both human apolipoprotein B and human CETP have a lipoprotein cholesterol distribution similar to that of normolipidemic humans J. Lipid Res. 1995, 36, 1082-1091
32. Gotto, A. M., Jr.; Cannon, C. P.; Li, X. S.; Vaidya, S.; Kher, U.; Brinton, E. A.; Davidson, M.; Moon, J. E.; Shah, S.; Dansky, H. M.; Mitchel, Y.; Barter, P. Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease Am. J. Card. 2014, 113, 76-83
33. Blasi, E.; Bamberger, M.; Knight, D.; Engwall, M.; Wolk, R.; Winter, S.; Betts, A.; John-Baptiste, A.; Keiser, J. J. Effects of CP-532,623 and torcetrapib, cholesteryl ester transfer protein inhibitors, on arterial blood pressure Cardiovasc. Pharmacol. 2009, 53, 507-516
34. Schmelting, B.; Niehoff, M.; Weinbauer, G. F. Integration of hemodynamic endpoints into toxicology studies: Torcetrapib and high definition oscillometry (HDO) in cynomolgus monkeys J. Pharmacol. Toxicol. Methods 2010, 62, e42
35. Levine, D. M.; Sloan, B. J.; Donner, J. E.; Lorenz, J. D.; Heinzerling, R. H. Automated measurement of lipoprotein(a) by immunoturbidimetric analysis Int. J. Clin. Lab. Res. 1992, 22, 173-178